PPP2CA Recombinant antibody

PPP2CA Uni-rAb^TM Recombinant Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

WB, ELISA

Conjugate

Unconjugated

CloneNo.

241112A6

Cat no : 84155-2-RR

Synonyms

---

Validation Data Gallery

• 

  WB analysis using 84155-2-RR

  Various lysates were subjected to SDS PAGE followed by western blot with 84155-2-RR (PPP2CA antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours.

---

Tested Applications

• Positive WB detected in: Jurkat cells, HeLa cells, HEK-293T cells, MCF-7 cells, mouse brain tissue

Recommended dilution

• Western Blot (WB): WB : 1:5000-1:50000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

84155-2-RR targets PPP2CA in WB, ELISA applications and shows reactivity with human, mouse samples.

• Tested Reactivity: human, mouse
• Host / Isotype: Rabbit / IgG
• Class: Recombinant
• Type: Antibody
• Immunogen: PPP2CA fusion protein Ag4294
• Full Name: protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform
• Calculated Molecular Weight: 309 aa, 36 kDa
• Observed Molecular Weight: 36 kDa
• GenBank Accession Number: BC031696
• Gene Symbol: PPP2CA
• Gene ID (NCBI): 5515
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Protein A purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

PPP2CA, also named as RP-C and PP2A-alpha, belongs to the PPP phosphatase family and PP-1 subfamily. PP2A can modulate the activity of phosphorylase B kinase casein kinase 2, mitogen-stimulated S6 kinase, and MAP-2 kinase. PP2A activity was modestly decreased in AML patients harboring C-KIT/WT.PP2A is a target for C-KIT/TKD and implicated the potential efficacy of therapies targeting PP2A in such AML in future.